Microchip Technology Incorporated

The stock is in a longer-term recovery regime, trading above its 200-day average of 73.4 after a strong run from the 52-week low of 47.6. It remains below the 52-week high of 105.4, so the setup is constructive but still mid-range rather than fully extended.

Wall Street stays constructive: the consensus is Buy with a 107.82 target, above the last close and supported by 30 Buy ratings versus 14 Holds and no Sells. Recent action has been mostly reaffirmations and target raises, with UBS, Needham, Susquehanna, and others lifting targets into the 105-135 range.

The next report carries a favorable beat backdrop: Microchip has topped EPS in 5 of the last 7 quarters, including a 61.5% upside surprise in the most recent print. Analysts see 2026 EPS at 1.57 and 2027 EPS rising to 3.15, so shareholders should watch whether margin recovery and demand translate into a cleaner forward guide.

Recent insider activity leans negative on discretionary trades, with multiple open-market sales from the COO, CFO, and a director. Several May 15 filings also include automatic award, exempt, and in-kind transactions, which are noise; the signal is the cluster of sales rather than any offsetting buying.

Profitability is improving but still modest: gross margin is 57.7% and operating margin is 17.1%, while net margin is 4.9%. Revenue grew 35.1% year over year, and free cash flow was $1.05 billion in fiscal 2026, giving the business solid cash generation despite low ROE of 3.4%.

Microchip’s broad embedded-control portfolio gives it a diversified position across automotive, industrial, and communications end markets, but its valuation is richer than many semiconductor peers at 54.4x earnings. The setup favors investors who want a recovery story with cash flow, not a deep-value multiple.